A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.

Other illness

• History of atrial septal defect repair or atrial myxoma
• History of cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack)
• History of cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision)
• Patients with acute or severe systemic infection
• Patients with severe liver or kidney disease
• Patients with significant bleeding tendencies or haematological disorders
• Patients with malignant tumours or end-stage diseases

Lab values

• Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%

Age

• Reproductive-age patients who cannot use effective contraception within 12 months of enrolment

Other

• Post-ablation for atrial fibrillation
• Left atrial thrombus
• Patients deemed ineligible for this trial by the investigator

• Patient age between 18 and 80 years old, male or non-pregnant female.
• Confirmed diagnosis of paroxysmal atrial fibrillation requiring catheter radiofrequency ablation surgery.
• Fully understands the treatment plan and voluntarily signs the informed consent form, willing to undergo the examinations, surgery, and follow-up required by the plan.